GGHC
CYNA

Gilder Gagnon Howe & Co’s CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) CYNA Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio CYNA Stock Details CYNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-43,541
Closed -$729K – 301
2016
Q2 		$729K Sell
43,541
-6,220
-12% -$83.7K 0.01% 195
2016
Q1 		$592K Buy
49,761
+1,340
+3% +$17.9K 0.01% 175
2015
Q4 		$740K Sell
48,421
-381
-0.8% -$5.79K 0.01% 184
2015
Q3 		$789K Buy
+48,802
New +$792K 0.01% 195

Other funds holding CYNA

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BHMP
Bardin Hill Management Partners New York $80.3M AUM 31.39% 1-Year Est. Return
CC
Coastland Capital Palo Alto, California $1.6B AUM 29.3% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Gilder Gagnon Howe & Co's CYNA Position: Q3 2016 in Review

Gilder Gagnon Howe & Co sold out of CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) (CYNA) in Q3 2016, closing a stake of 43,541 shares — an estimated $729K sold.

Gilder Gagnon Howe & Co first reported a position in CYNA in Q3 2015 and held it in 4 quarters. The position peaked at $789K in Q3 2015. 60 funds tracked by Wall St. Rank hold CYNA as of Q3 2016.

  • Gilder Gagnon Howe & Co reported no remaining CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) position as of Q3 2016 after selling out during the quarter.
  • Gilder Gagnon Howe & Co sold 43,541 CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) shares in Q3 2016, an estimated $729K.
  • Gilder Gagnon Howe & Co first reported a position in CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) in Q3 2015 and held it in 4 quarters.
  • Gilder Gagnon Howe & Co's CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) position peaked at $789K in Q3 2015.
  • 60 funds tracked by Wall St. Rank held CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) as of Q3 2016.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2016, filed 1 Nov 2016.